This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Dec;26(12):2361-2.

doi: 10.1093/annonc/mdv497. Epub 2015 Oct 20.

Immunity and HER2-positive disease: never stop questioning

S Loi¹

Affiliations

PMID: 26487579
DOI: 10.1093/annonc/mdv497

Free article

Editorial

Immunity and HER2-positive disease: never stop questioning

S Loi. Ann Oncol. 2015 Dec.

Free article

. 2015 Dec;26(12):2361-2.

doi: 10.1093/annonc/mdv497. Epub 2015 Oct 20.

Author

S Loi¹

Affiliation

¹ Division of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia sherene.loi@petermac.org.

PMID: 26487579
DOI: 10.1093/annonc/mdv497

No abstract available

PubMed Disclaimer

Comment on

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L. Bianchini G, et al. Ann Oncol. 2015 Dec;26(12):2429-36. doi: 10.1093/annonc/mdv395. Epub 2015 Sep 19. Ann Oncol. 2015. PMID: 26387142 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal